These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23750797)

  • 21. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
    Lawson LB; Norton EB; Clements JD
    Curr Opin Immunol; 2011 Jun; 23(3):414-20. PubMed ID: 21511452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intradermal immunization: an alternative route for vaccine administration. Articles as per sessions meeting report.
    Picot V
    Vaccine; 2008 Dec; 26 Suppl 9():S1-5. PubMed ID: 19268138
    [No Abstract]   [Full Text] [Related]  

  • 23. The path to a successful vaccine adjuvant--'the long and winding road'.
    O'Hagan DT; De Gregorio E
    Drug Discov Today; 2009 Jun; 14(11-12):541-51. PubMed ID: 19508916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization.
    Zhao YL; Murthy SN; Manjili MH; Guan LJ; Sen A; Hui SW
    Vaccine; 2006 Feb; 24(9):1282-90. PubMed ID: 16225969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conjugation of protein antigen to microparticulate beta-glucan from Saccharomyces cerevisiae: a new adjuvant for intradermal and oral immunizations.
    Berner VK; Sura ME; Hunter KW
    Appl Microbiol Biotechnol; 2008 Oct; 80(6):1053-61. PubMed ID: 18677470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioadhesive delivery systems for mucosal vaccine delivery.
    Baudner BC; O'Hagan DT
    J Drug Target; 2010 Dec; 18(10):752-70. PubMed ID: 21039314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcutaneous immunization: an overview of advantages, disease targets, vaccines, and delivery technologies.
    Karande P; Mitragotri S
    Annu Rev Chem Biomol Eng; 2010; 1():175-201. PubMed ID: 22432578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems.
    Gupta RK; Chang AC; Siber GR
    Dev Biol Stand; 1998; 92():63-78. PubMed ID: 9554260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Vaccines: intradermal, poliomyelitis, aluminum].
    Nau JY
    Rev Med Suisse; 2012 Nov; 8(364):2308-9. PubMed ID: 23240250
    [No Abstract]   [Full Text] [Related]  

  • 30. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.
    Nordly P; Madsen HB; Nielsen HM; Foged C
    Expert Opin Drug Deliv; 2009 Jul; 6(7):657-72. PubMed ID: 19538037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methods of immunization to enhance the immune response to specific antigens in vivo in preparation for fusions yielding monoclonal antibodies.
    Rudbach JA; Cantrell JL; Ulrich JT
    Methods Mol Biol; 1995; 45():1-8. PubMed ID: 7550673
    [No Abstract]   [Full Text] [Related]  

  • 32. Advances in transcutaneous vaccine delivery: do all ways lead to Rome?
    Bal SM; Ding Z; van Riet E; Jiskoot W; Bouwstra JA
    J Control Release; 2010 Dec; 148(3):266-82. PubMed ID: 20869998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intradermal vaccine delivery: will new delivery systems transform vaccine administration?
    Lambert PH; Laurent PE
    Vaccine; 2008 Jun; 26(26):3197-208. PubMed ID: 18486285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of soluble inulin microparticles as a potent and safe vaccine adjuvant and delivery system.
    Kumar S; Tummala H
    Mol Pharm; 2013 May; 10(5):1845-53. PubMed ID: 23506468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential of CpG oligodeoxynucleotides as mucosal adjuvants.
    McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
    Crit Rev Immunol; 2001; 21(1-3):103-20. PubMed ID: 11642598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resiquimod and other immune response modifiers as vaccine adjuvants.
    Tomai MA; Miller RL; Lipson KE; Kieper WC; Zarraga IE; Vasilakos JP
    Expert Rev Vaccines; 2007 Oct; 6(5):835-47. PubMed ID: 17931162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization.
    Stano A; Nembrini C; Swartz MA; Hubbell JA; Simeoni E
    Vaccine; 2012 Dec; 30(52):7541-6. PubMed ID: 23103199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [An update on vaccines. Theory, realities and myths (I)].
    Martínez-Mateo P; Bustos-Fonseca MJ; Gil-Díaz MJ
    Semergen; 2012 Apr; 38(3):160-6. PubMed ID: 24895720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Devices for intradermal vaccination.
    Kis EE; Winter G; Myschik J
    Vaccine; 2012 Jan; 30(3):523-38. PubMed ID: 22100637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.
    Dey AK; Srivastava IK
    Expert Rev Vaccines; 2011 Feb; 10(2):227-51. PubMed ID: 21105782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.